A systematic review assessing occurrence of medication-related osteonecrosis of the jaw following dental procedures

Shimelly Monteiro de Castro Lara¹, Francisco Wilker Mustafa Gomes Muniz²*, Ana Beatriz Caetano Gerônimo¹, Cinthia Studzinski dos Santos³, Thayanne Brasil Barbosa Calcia¹

Aim: This study aimed to systematically review existing literature regarding the association between dental procedures—such as tooth extractions and periodontal therapy—and occurrence of medication-related osteonecrosis of the jaw (MRONJ) in individuals using bone-modifying drugs. Methods: Search strategies were performed in PubMed, Scopus, Web of Science and Cochrane Library for a timeframe ending in December 2021. Study selection, data extraction and risk of bias were analyzed independently by two researchers. Three meta-analyses were performed, estimating the crude risk ratio (RR), the adjusted odds ratio (OR) and the adjusted hazard ratio (HR) for the association between tooth extraction and MRONJ. Results: Of the 1,654 studies initially retrieved, 17 were ultimately included. The majority of patients with MRONJ in these studies were female, with a mean age of 64 years. Zoledronic acid was the most commonly used drug among patients with MRONJ, and cancer was the most frequent underlying health condition. Regarding the performed meta-analyses, crude and adjusted analyses demonstrated that tooth extraction increased the risk for MRONJ by 4.28 (95% confidence interval [95%CI]: 1.73–10.58), the OR for MRONJ by 26.94 (95%CI: 4.17–174.17), and the HR for MRONJ by 9.96 (95%CI: 4.04–24.55). Conclusion: It was concluded that performing dental procedures, especially tooth extraction, in patients using bone-modifying drugs increased the risk of MRONJ occurrence and, therefore, should be avoided. Further studies, using adjusted data, are warranted. Keywords: Bisphosphonate-associated osteonecrosis of the jaw. Bone density conservation agents. Diphosphonates. Osteonecrosis. Surgery, oral.
Introduction

Dental treatment currently presents new challenges among professionals due to the increasing prevalence of patients with cancer and other comorbidities, conditions which are frequently treated with bone-modifying drugs such as bisphosphonates and antiresorptive agents\(^1\). Bisphosphonates are well-tolerated and extensively used as treatment for bone-related diseases, reducing risk of vertebral fractures and bone loss due to steroid-based treatment\(^2\). However, in the early 2000’s, an important adverse effect related to these drugs was reported. Several patients exhibited necrotic bone in the jaw, often refractory towards surgical debridement, a clinical feature later denominated as bisphosphonate-related osteonecrosis of the jaw (BRONJ)\(^3-5\).

In ensuing decades, this condition has also been connected to other drugs such as antiresorptive and angiogenesis-inhibiting agents, including (respectively) denosumab and bevacizumab, despite their different mechanisms of action\(^6,7\). Recently, the newer terminology of medication-related osteonecrosis of the jaw (MRONJ) was adopted in order to include these drugs\(^8\). The occurrence of MRONJ seems to be highly variable, running from very rare to common (0.01–1%) depending on multiple factors both drug-related and independent\(^9\). Clinically, this condition presents as an avascular exposed bone or bone that can be probed through an intraoral or extraoral fistula on the maxilla or mandible\(^8,10\). Furthermore, an MRONJ diagnosis is based on current or previous exposure to antiresorptive or antiangiogenic agents with no history of radiotherapy or metastatic jaw disease\(^8\).

MRONJ is most often observed in older women, since this group of patients is more likely to be treated with antiresorptives due to conditions such as breast cancer or osteoporosis\(^11\). This disease can present different degrees of complexity, and a classification according to staging systems has been proposed; at present, every patient under antiresorptive therapy is considered at risk\(^10\). In this sense, MRONJ presentation can vary from an asymptomatic exposed bone with no further clinical complication to a lesion with extensive bone involvement, extraoral communication and infection\(^10\). Thus, it is an important oral complication, one for which treatment can be difficult and often ineffective\(^12\). Its etiology seems to be related to drug dosage, administration route, therapy duration and comorbidities (e.g., diabetes or a smoking habit)\(^13\). Antiresorptives and/or antiangiogenics usually demand higher doses when prescribed in cancer treatment, which has also been associated with an increased risk\(^8\). Additionally, use of corticosteroids and/or immunosuppressants may also be related to MRONJ\(^14\). However, there is no consensus about how these factors can influence MRONJ occurrence\(^12\).

Crucially, oral surgical procedures are frequently identified as MRONJ precipitating events; therefore, elective procedures are often unadvised\(^8\). As a result, MRONJ occurrence has become a challenge for dental professionals in recent years due to the absence of predictive factors providing security for dental intervention\(^10\). However, MRONJ can also occur without a history of oral surgical treatment\(^15\). Thus, this study aimed to systematically review current literature regarding the association
between dental procedures and MRONJ in patients with current or historical use of bone-modifying agents.

**Material and Methods**

**PICO question**

A systematic review was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines\(^\text{16}\). The present study focused on answering the following clinical question: "Do dental extractions and periodontal surgeries increase the risk of MRONJ in patients in current therapy or with a history of antiresorptive and/or antiangiogenic use?" Therefore, the PICO question was structured as follows: Population: antiresorptive and/or antiangiogenic users or those with a use history; Intervention: extractions and periodontal therapy; Comparison: absence of dental interventions; Outcome: occurrence of MRONJ.

**Search strategy**

Electronic search strategies were performed in order to include studies published up to December 2021. The search strategies were applied in the Medline-PubMed, Web of Science, Scopus, and Cochrane Library databases, and are presented in Table 1. Grey literature was also searched using the New York Academy of Medicine (NYAM) gray literature report and Google Scholar databases. An adaptation of the search strategies described in Table 1 was performed on both databases. In Google Scholar, the first 300 studies were searched, as recommended by the literature\(^\text{17}\).

In order to be included in this study, studies from the search results had to involve clinical trials (randomized or not), case-controls, case series (minimum of ten patients) and prospective or retrospective cohorts. Furthermore, studies had to involve current or former users of bone-modifying agents (antiresorptive and/or antiangiogenic drugs). The study group had to be composed of individuals submitted to dental extraction and/or periodontal surgical procedures. The control group had to include those who had not undergone the previously reported dental procedures. Literature reviews, in vitro studies, animal studies and case reports were excluded.

**Study selection**

References obtained through the described search strategy were organized, and duplicates were removed using the EndnoteWeb\(^\text{®}\) program (Clarivate Analytics). Study selection was carried out independently by two reviewers (ABGC and SMCL) in consideration of the inclusion criteria. In case of disagreement, a consensus was reached through discussion. Subsequently, full texts were independently evaluated for final selection. Three reviewers (ABGC, SMCL and TBBC) were included in this step and a fourth reviewer (FWMGM) was consulted to resolve possible disagreements. Additionally, a manual search was performed on the references list of selected studies.
### Table 1. Search strategies performed and number of studies detected in all databases.

<table>
<thead>
<tr>
<th>Database</th>
<th>Search strategy</th>
<th>Number of studies retrieved</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>#4 - #1 AND #2 AND #3</td>
<td></td>
</tr>
<tr>
<td>Web of Science</td>
<td>#1 – TS=(Surgery, oral OR “Oral surgery” OR “Dental care” OR “Oral Surgical Procedures” OR “Tooth extraction” OR “dental extraction” OR “teeth extraction” OR “teeth removal” OR “tooth extraction” OR “Crown Lengthening” OR Gingivectomy OR Gingivoplasty OR “Dental Scaling” OR “Root Planing” OR “open flap debridement” OR “periodontal surgery” OR “Guided Tissue Regeneration” OR “root coverage” OR “gingival graft” OR “periodontal osseous surgery” OR “Periodontal treatment”)</td>
<td>899</td>
</tr>
<tr>
<td></td>
<td>#2 – TS=(Diphosphonates OR bisphosphonate OR bisphosphonates OR alendronate OR alendronate sodium OR “Risedronic Acid” OR Risedronate OR Pamidronate OR Amidronate OR Ibandronate OR “Ibandronic Acid” OR Zoledronate OR “Zoledronic Acid” OR “Clodronic Acid” OR Clodronate OR “Etidronic Acid” OR Denosumab OR “Antiresorptive drugs” OR Bevacizumab OR Sorafenib OR Sunitinib OR Pazopanib OR Axitinib)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#3 – TS=(Osteonecrosis OR “Bone Necrosis” OR ARONJ OR BRONJ OR ONJ OR MRONJ OR “osteonecrosis of the jaw” OR “bisphosphonate-related osteonecrosis of the jaw” OR “bisphosphonate-related ONJ” OR “bisphosphonate-associated osteonecrosis of the jaw” OR “medication-related osteonecrosis of the jaw”)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>#4 - #1 AND #2 AND #3</td>
<td></td>
</tr>
</tbody>
</table>

Continue
Data extraction was performed in a spreadsheet specifically developed for this study. Two researchers (SMCL and TBBC) were involved in this process, with a third
researcher involved in case of discrepancy (FWMGM). The following parameters were collected: author, publication year, country, study design, patient gender, mean (standard deviation [SD]) age, number of patients with and without MRONJ, MRONJ diagnosis criteria, number of patients submitted to dental procedures in both test and control groups, dental prosthesis users, smokers, use of bone-modifying drugs and its clinical indication and other medications reported. In cases of insufficient information, authors were contacted by email to obtain additional information.

Risk of bias assessment

Both retrospective and prospective cohorts as well as case-control studies were included in this review. Therefore, the Newcastle-Ottawa quality assessment tool was used to analyze the risk of bias in this study. This tool consists of eight criteria and classifies the involved research according to a score ranging from zero to nine stars. On this scale, a study can be awarded a maximum of one star for each item within the selection and outcome categories. In the comparability category, it is possible to award the study with two stars. The first star is received by studies that performed control for the most important factor. The second is received by studies that carried out controls on other additional factors. The risk of bias analysis was performed independently by two reviewers (CSS and TBBC), and discrepancies were solved by a third researcher (FWMGM).

Data synthesis and statistical analysis

Three different meta-analyses were conducted during this study. Meta-analyses were performed if at least two studies provided enough information regarding the occurrence of MRONJ following dental surgical procedures. No study clearly reported the occurrence of MRONJ after periodontal surgical procedures. Thus, three meta-analyses were performed for tooth extraction procedures regardless of the study follow-up time. Firstly, MRONJ risk involving dental extraction was assessed using risk ratio (RR). Additionally, two other meta-analyses were performed using the pooled log of odds ratio (OR) and the pooled log of hazard ratio (HR); this was done only for studies that provided multivariate estimates for the occurrence of MRONJ following dental extraction, controlling for at least two important confounding variables. Heterogeneity was assessed using the Q test and quantified by I². For both analyses, a random model was used within the Review Manager software (version 5.3).

Results

Search results

Firstly, a total of 3,725 studies were obtained through our search strategy. Four additional studies were included as the result of a manual search on the final references list of included articles. After duplicates removal, 1,654 studies were screened; of those, 85 were assessed for eligibility. Seventeen studies fulfilled the outlined inclusion criteria and were included in the qualitative synthesis. Therefore, 13 retrospective cohorts18-30, one prospective cohort31 and three case-control studies32-34 were included in the present study, as shown in Figure 1.
Risk of bias assessment

The risk of bias assessment conducted on the cohort studies is summarized in Figure 2A. Among the different cohort studies, eight20-23,25,27-29 presented low risk of bias in all analyzed criteria. Four cohort articles presented a high risk of bias regarding comparability between groups, given the presence of possible confounders18,19,24,31. Additionally, four studies failed to demonstrate that the outcome was not present at the beginning of the study19,26,30,31. Figure 2B presents the risk of bias assessment for the case-control studies. Only one case-control study presented a low risk of bias in all analyzed criteria34. Moreover, among case-control studies, risk of bias in relation to non-response rate between groups was detected in two studies, which were thus classified as presenting a high risk of bias32,33.

Main results

The main characteristics of the included studies with patients subject to bone-modifying therapies are summarized in Table 2. The number of patients enrolled had great variability among studies, with a range from 39 to 164,926 individuals. Over-

Figure 1. PRISMA flowchart of study selection process. Legend: RR: Risk ratio; aOR: adjusted odds ratio; aHR: adjusted hazard ratio.
Figure 2. Risk of bias analysis of cohort (A) and case-control (B) studies, according to Newcastle-Ottawa scale.
Table 2. Main characteristics of patients using bone-modifying drugs enrolled in the studies.

<table>
<thead>
<tr>
<th>Author/Year</th>
<th>Country</th>
<th>Study design</th>
<th>MRONJ/ All patients</th>
<th>Bone-modifying drug</th>
<th>Clinical indication; Current medications</th>
<th>Oral surgical procedures; Dental prosthesis; Oral infections</th>
<th>Diabetes; Smokers</th>
<th>Main results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Incidence (%)</td>
<td>Mean age</td>
<td>Drug-related factors</td>
<td>MRONJ All</td>
<td>Non-MRONJ</td>
<td>MRONJ</td>
</tr>
<tr>
<td>Bonacina (2011) Canada; Prospective cohort.</td>
<td>7/65 (10.7%)</td>
<td>NR</td>
<td>Zoledronate (7)</td>
<td>Zoledronate (55) and sunitinib (3)</td>
<td>Cancer (7); Corticoids (0)</td>
<td>Extraction (1); NR; NR</td>
<td>NR; 0</td>
<td>NR; 13</td>
</tr>
<tr>
<td>Calvo-Villas (2016) Spain; Retrospective cohort.</td>
<td>7/64 (10.9%)</td>
<td>75 yo</td>
<td>Zoledronate (3)</td>
<td>Zoledronate (57) and zoledronate (43)</td>
<td>Multiple myeloma (7); Corticoids (7) Thalidomide (3)</td>
<td>Extraction (5); NR; Oral infection (6)</td>
<td>Extraction (1); NR; Oral infection (44)</td>
<td>NR; 2</td>
</tr>
<tr>
<td>Carmagnola (2008) Italy; Retrospective cohort.</td>
<td>20/39 (51.7%)</td>
<td>65 yo</td>
<td>Zoledronate (19)</td>
<td>Zoledronate (18)</td>
<td>Cancer (14) Multiple myeloma (6); NR</td>
<td>Extraction (10); Dentures (7); NR</td>
<td>Extraction (5); NR</td>
<td>NR; NR</td>
</tr>
<tr>
<td>Gunaldi (2015) Turkey; Case-Control</td>
<td>24/44 (54.4%)</td>
<td>60,5 yo</td>
<td>Zoledronate (23)</td>
<td>Zoledronate (19)</td>
<td>Cancer (14) Multiple myeloma (8) Other (2); Corticoids (7) Thalidomide (5)</td>
<td>Extraction (13); NR; NR</td>
<td>Extraction (4); NR</td>
<td>NR; NR</td>
</tr>
</tbody>
</table>

Continue
<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Retrospective cohort</th>
<th>Mean time of treatment and dental extractions were related to occurrence of MRONJ. Use of zoledronate increases risk of osteonecrosis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hoff (2008)</td>
<td>USA</td>
<td>29/3965 (0.79%) 62yo</td>
<td>Pamidronate (7) Zoledronate (9) Pamidronate + Zoledronate (13) Cancer (16) Multiple myeloma (13); Corticoids (23) Cancer (2392) Multiple myeloma (535) Osteoporosis (271) Paget's disease (11); Corticoids (3272) Extraction (16); Dentures (3); Oral infection (14) Extraction (136); NR; NR NR; NR NR; NR NR; NR</td>
</tr>
<tr>
<td>Ikesue (2021)</td>
<td>Japan</td>
<td>34/374 (9.09%) 70yo</td>
<td>Denosumab (27) Zoledronate (7) Cancer (28) Multiple myeloma (4) Others (2) Oral bisphosphonate (1) Antiangiogenic agents (11) Corticoid (22) Cancer (246) Multiple myeloma (52) Others (40) Oral bisphosphonate (12) Antiangiogenic agent (62) Corticoid (181) Extraction (10); NR; NR Extraction (10); NR; NR 3; NR 67; NR</td>
</tr>
<tr>
<td>Ikesue (2021)</td>
<td>Japan</td>
<td>58/799 (7.3%) NR</td>
<td>Denosumab (39) Zoledronate (19) Denosumab (367) Zoledronate (374) NR NR NR NR NR; NR; NR NR; NR; NR NR; NR; NR NR; NR; NR NR; NR; NR NR; NR NR; NR</td>
</tr>
<tr>
<td>Ikesue (2021)</td>
<td>Japan</td>
<td>65/795 (8.2%) NR</td>
<td>Denosumab after Zoledronate (7) Zoledronate (36) Denosumab after Zoledronate (31) Denosumab (363) NR NR NR NR NR; NR; NR NR; NR; NR NR; NR; NR NR; NR; NR NR; NR; NR</td>
</tr>
<tr>
<td>Continue</td>
<td></td>
<td></td>
<td>Incidence of MRONJ was greater in the denosumab group than in zoledronate users. MRONJ occurrence was related to age &gt; 65 years and tooth extraction before or after starting therapy.</td>
</tr>
<tr>
<td>Continue</td>
<td></td>
<td></td>
<td>Risk of developing MRONJ was higher in denosumab users. Tooth extraction after starting therapy was a significant risk factor to develop MRONJ.</td>
</tr>
<tr>
<td>Continue</td>
<td></td>
<td></td>
<td>MRONJ occurrence was associated with tooth extraction, concomitant use of antiangiogenics, denosumab therapy and switching zoledronate to denosumab.</td>
</tr>
<tr>
<td>Study</td>
<td>Country</td>
<td>Design</td>
<td>Patients</td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>Jadu (2007)</td>
<td>Canada</td>
<td>Retrospective cohort</td>
<td>21/655 (3.2%)</td>
</tr>
<tr>
<td>Kim (2021)</td>
<td>South Korea</td>
<td>Retrospective cohort</td>
<td>166/164,926 (0.1%)</td>
</tr>
<tr>
<td>Kyrgidis (2008)</td>
<td>Greece</td>
<td>Case-Control</td>
<td>20/60 (NA)</td>
</tr>
<tr>
<td>McGowan (2019)</td>
<td>Australia</td>
<td>Case-control</td>
<td>44/159 (NA)</td>
</tr>
<tr>
<td>Matsui (2015)</td>
<td>Japan</td>
<td>Retrospective cohort</td>
<td>23/106 (21.6%)</td>
</tr>
</tbody>
</table>
Continuation

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Design</th>
<th>Cases/N ( % )</th>
<th>Features Reported</th>
<th>MRONJ (Cases)</th>
<th>Other (Cases)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soutome (2021)</td>
<td>Japan Retrospective cohort</td>
<td>33/359 jaws/NA 65.9</td>
<td>Bisphosphonate not specified (149 jaws) Denosumab (169 jaws) Bisphosphonate to denosumab</td>
<td>Cancer (33 jaws) Corticosteroid (3 jaws)</td>
<td>Tooth extraction (5 jaws) Oral infection (13 jaws)</td>
<td>4; 3 34; 54</td>
</tr>
<tr>
<td>Ueda (2021)</td>
<td>Japan Retrospective cohort</td>
<td>43/745 NA NR</td>
<td>Bisphosphonate not specified (11) Denosumab (26) Bisphosphonate not specified plus denosumab (5)</td>
<td>Cancer (43)</td>
<td>Tooth extraction (6)</td>
<td>NR;NR</td>
</tr>
<tr>
<td>Ueda (2021)</td>
<td>Japan Retrospective cohort</td>
<td>42/398 (10.6%) 70.5</td>
<td>Bisphosphonate not specified (136) Denosumab (179) Bisphosphonate not specified plus denosumab (41)</td>
<td>Cancer (42) Multiple myeloma (3) Corticoid (1)</td>
<td>Tooth extraction (5)</td>
<td>4;14 51; 68</td>
</tr>
<tr>
<td>Valtsevanos (2009)</td>
<td>Greece Retrospective cohort</td>
<td>80/1621 (4.93%) 63.6</td>
<td>Bisphosphonate not specified (80) Bisphosphonate not specified (1541)</td>
<td>Cancer (34) Multiple myeloma (46) Cancer (1048) Multiple myeloma (493)</td>
<td>Tooth extraction (46) Dentures (24) Tooth extraction (69) Dentures (199)</td>
<td>NR;42 NR;826</td>
</tr>
</tbody>
</table>

MRONJ – Medication-related osteonecrosis of the jaw; NR = Not reported; YO; years old; NA = not applicable
all, 175,004 patients were included in the seventeen studies, with mean age ≥ 60 years. A higher percentage of female patients was reported among the majority of included studies. Male patients were more prevalent in only five studies, while three studies did not provide data regarding sex. AAOMS classification diagnostic criteria was adopted in ten studies. Among the included studies, a total of 683 patients with MRONJ were enrolled. This condition had a slightly higher diagnosis rate among female patients (n = 129/256), when considering studies that provided this information. Among individuals with MRONJ, 159 patients had a history of tooth extraction, representing 23.2% of the total. Use of dental prosthesis was reported in 60 patients, after an analysis of 196 individuals (30.6%). However, it is important to note that this variable was not reported in most of the studies. Smoking was also assessed as a possible risk factor for MRONJ; this factor was reported in two studies. Among 966 individuals who reported smoking habits, 89 patients developed MRONJ. The main reason for clinical indication of the use of antiresorptive and antiangiogenic drugs was cancer (209 patients, 30.6%). Among the drugs used, Zoledronate was the most cited (143 patients, 20.9%). When considering corticosteroid use and occurrence of MRONJ, studies reported prevalence varying from 2.3% to 29%, 64.7%, 79% and up to 100% of patients, among five studies that provided this information (Table 2). It is important to highlight that, aside from the provided data, one study was not included in the quantitative synthesis, as only the number of jaws (not patients) was available.

Regarding patients without MRONJ, the total number of patients varied among studies, with a total sample of 174,132. There was once again a higher prevalence of female individuals involved, but the main underlying disease reported was osteoporosis (165,152 patients, 94.8%), mostly due to one expressive cohort study. For patients without MRONJ, pamidronate was the most frequently reported drug used; however, several studies did not specify the bisphosphonate agent. The use of dental prostheses was reported for 259 patients. Additionally, smoking was observed in 0.5% of patients, for a total of 1,010 individuals (Table 2).

Meta-analyses

Only dental extraction procedures were reported in all selected studies. For this reason, this was the only dental procedure available to include in meta-analyses. Crude analysis revealed an increase in the relative risk of occurrence of MRONJ following tooth extraction (RR = 4.28; 95%CI: 1.73–10.58), as presented in Figure 3. For this analysis, eleven studies were included. It is important to highlight the high heterogeneity among these studies (I² = 95%, p<0.001).

Furthermore, two additional meta-analyses were performed in consideration only of the studies that reported adjusted analysis for the association between dental extraction and MRONJ. Three studies assessed the adjusted OR, and four estimated the adjusted HR. As shown in Figures 4 and 5, similar results were demonstrated, as dental extraction significantly increased the OR for the occurrence of MRONJ (OR = 26.94; 95%CI: 4.17–174.17%) and the HR for the occurrence of MRONJ (HR = 9.96; 95%CI: 4.04–24.55). Moreover, high heterogeneity was demonstrated in both analyses (respectively: I² = 84%, p=0.002; and I² = 80%, p=0.002).
Discussion

MRONJ is a recently described complication, first reported in 2003 through a series of cases in patients who used bisphosphonates. Since then, several reports have associated avascular bone necrosis with oral and intravenous bisphosphonates therapy, in addition to antiresorptives and antiangiogenics.

Due to its multifactorial nature and complex management, many authors have tried to associate risk factors with MRONJ development in order to avoid its occurrence. The present study identified that the occurrence of MRONJ is generally higher among women, which is in accordance with the literature. Osteoporosis and breast cancer, the therapeutic indications of which are related to the use of antiresorptives, bisphosphonates and antiangiogenics, are more common among female patients, which may explain this result. In addition to these factors, literature reports that women seek more often dental care; this could result in a higher diagnosis rate for several conditions, including MRONJ.
The mean age of patients diagnosed with MRONJ was greater than 60 years in the included studies, which is in accordance with the literature\textsuperscript{39,40}. Among these patients, there is a higher incidence of chronic diseases—a common reason for prescribing bone-modifying drugs—and few studies failed to detect this relationship\textsuperscript{30}.

Trigger factors for MRONJ remain subject to critical investigation. Marx\textsuperscript{3} reported its occurrence more often following dental procedures in the mandible. Among the studies included here, tooth extraction, periodontal disease or trauma induced by poorly adapted prostheses have been involved in the onset and even exacerbation of the condition\textsuperscript{20,21}. Bone exostosis, trauma induced by intubation and poor dental implant placement have also been discussed\textsuperscript{20}.

Dental extractions can be justified as a risk factor for the development of MRONJ, as they may induce bone exposure in the oral cavity with a consequent reduction in blood support and bone metabolism and greater osteoclast apoptosis\textsuperscript{19}. The present study confirms the proposed association between tooth extraction and MRONJ onset, including in the adjusted analysis. In fact, MRONJ occurs frequently at the procedure site, although it can also occur spontaneously (i.e., without an identifiable precipitating clinical event)\textsuperscript{41}. According to Carmagnola et al.\textsuperscript{19}, patients with MRONJ reported extractions twice as frequently as those without MRONJ. However, analysis also revealed a high heterogeneity, which can be attributed to different experimental designs and varied sampling. Moreover, due to the lack of randomized controlled trials, this research included only cohort and case-control studies; as a result, it is difficult to provide solid evidence regarding this research topic, which explains the fact that several recommendations for the management of MRONJ are based on expert consensus\textsuperscript{10}. Hence, this must be taken into consideration when interpreting the results of the present study.

Other local factors may also be involved in the occurrence of MRONJ. Teeth with dental extraction indication are often associated with an infectious process, and the presence of inflammation or infection would be a predisposing factor for the appearance of lesions caused by avascular bone necrosis\textsuperscript{41}. In this regard, one study found that MRONJ occurrence may also be related to preexisting inflammatory dental disease; in such a scenario, dental extraction is fundamental in order to prevent MRONJ onset\textsuperscript{27}. Furthermore, the use of dental prostheses, which is common among older adults, is considered another potential local risk factor for MRONJ. Unretained dental prosthesis may cause low-grade chronic trauma, usually resulting in oral lesions due to rupture of the protective barrier which allow the entry of highly contaminated oral microbiota into the bone\textsuperscript{29,32}.

In addition, systemic factors can also influence the occurrence of MRONJ. One critical example is diabetes, a disease that can predispose a patient to the occurrence of this dental complication\textsuperscript{40}. In the present study, two included studies suggested that type II diabetes and smoking represent important risk factors for the occurrence of MRONJ\textsuperscript{31,33}. Moreover, exposure to smoke predisposes a patient to cancer, making the need for administration of antiresorptive and antiangiogenic drugs more likely and thus intrinsically increasing the possibility of MRONJ, complicating the identification of a cause-and-effect relationship\textsuperscript{33}. Conversely, two previous studies did not state an association between smoking and MRONJ\textsuperscript{18,30}. 


Current use of other medications, such as corticosteroids, has also been listed as a risk factor in the literature. One included study reported that all MRONJ patients were also using corticosteroids, while another reported this percentage as 2.3%. Therefore, based on compiled data, there is no way to draw a definitive conclusion on this topic.

Bisphosphonate or antiresorptive type, form of administration (oral or IV), number of infusions and the time of exposure are also factors considered in relation to the development of MRONJ. Among the included studies, a higher percentage of patients with MRONJ undergoing cancer treatment was observed. However, due to lack of information regarding time of therapy and dosage, it was not possible to further analyze these characteristics in the present study. That said, the majority of studies found a correlation between cumulative doses and MRONJ.

The included studies ultimately reveal that there is not yet enough evidence to ensure safe invasive dental procedures in such patients, even after the interruption of the therapeutic protocol. Therefore, communication between health care professionals is essential to provide preventive treatment prior to drug administration. Routine and preventive appointments for early identification of infectious areas are fundamental for preventing MRONJ and reducing the significant impact of this complication. It must be noted that the present study was not previously registered in any database of protocols for systematic reviews. Unfortunately, a posteriori registrations are not permitted by these databases. This must therefore be understood as a major limitation of the present study.

In summary, this systematic review showed that dental extractions increased the risk of MRONJ occurrence 4.28 times. Risk factors such as smoking, diabetes and the use of corticosteroids are possible variables related to this condition, which is more frequent in women over 60 years of age. Our work adds vital evidence in order to provide better care for these patients. Preventive oral hygiene measures are the best options available for patients using bone-modifying drugs, preferably before the start of medical and dental procedures.

Acknowledgments
This study was financed in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. All other funding was self-supported by the authors. The authors report no conflict of interest.

Data availability
Datasets related to this article will be available upon request to the corresponding author.

Conflict of Interests
None.

Author contribution
Shimelly Monteiro de Castro Lara has contributed with study selection, data extraction and writing; Ana Beatriz Caetano Gerônimo was enrolled in study selection and data
extraction; Francisco Wilker Mustafa Gomes Muniz has contributed with conceptualization, methodological advice, designing search strategies, writing and final revision; Cinthia Studzinski Santos was enrolled in bias assessment and writing; Thayanne Brasil Barbosa Calcia has contributed with conceptualization, bias assessment, writing and final revision.

List of all captions

AAOMS: American Academy of Oral and Maxillofacial Surgery
BRONJ: bisphosphonate related osteonecrosis of jaw
CI: Confidence Interval
MRONJ: Medication Related Osteonecrosis of the Jaw
OR: odds ratio
PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses
RR: risk ratio

References


